NovAliX enters into fragment-based drug discovery alliance with Kyowa Hakko Kirin

17-Jan-2013 - France

NovAliX SAS announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.

Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.

Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.

Other news from the department research and development

Most read news

More news from our other portals

Last viewed contents

Sirius Genomics Announces Appointment of Senior Director of Business Development

LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany

LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany

Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for DiaPep277 for Type 1 Diabetes

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Stora Enso and Gasum to make renewable energy from wastewater in Sweden

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration

Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Antibiotic-Resistant Bacteria Have Evolved a Unique Chemical Mechanism, New Discovery Reveals

UF study strengthens concerns about long-term use of certain painkillers